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Purpose/Objective(s): Stereotactic body radiation therapy (SBRT) has been shown to
have increased local control and overall survival relative to conventional external beam
radiation therapy in patients with medically inoperable stage I non-small cell lung cancer
(NSCLC). Excellent rates of local control have been demonstrated both in clinical trials and
in single-center studies at large academic institutions. However, there is limited data on
the experiences of small academic hospitals with SBRT for stage I NSCLC. The purpose
of this study is to report the local control and overall survival rates in patients treated with
SBRT for stage I NSCLC atWinthrop-University Hospital (WUH), a small academic hospital.
Materials/Methods: This is a retrospective review of 78 stage I central and peripheral
NSCLC tumors treated between December 2006 and July 2012 with SBRT at WUH. Treat-
ment was given utilizing fiducials and a respiratory tracking system. If the fiducials were
not trackable, a spine tracking system was used for tumor localization. CT-based planning
was performed using the ray trace algorithm. Treatment was delivered over consecutive
days to a median dose of 4800 cGy delivered in four fractions. The Kaplan–Meier method
was used to calculate local control and overall survival.
Results:The median age was 78.5 years. Fifty-four percent of the patient population was
female. Sixty seven percent of the tumors were stage IA, and 33% of the tumors were
stage IB. Fifty-three percent of the tumors were adenocarcinomas and 29% were squa-
mous cell carcinomas, with the remainder being of unknown histology or NSCLC, not
otherwise specified The 2-year local control rate was 87%, and the 2-year overall survival
was 68%.
Conclusion:Our findings support that local control and overall survival at a small academic
hospital are comparable to that of larger academic institutions’ published experiences with
SBRT for stage I NSCLC.
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INTRODUCTION
Surgery is the standard of care for stage I non-small cell lung can-
cer (NSCLC) (1) with local recurrence rates quoted around 5%
(2, 3) and 5-year overall survival from 75 to 80% (4). In patients,
who are medically inoperable or refuse surgery, radiation therapy
is the next line treatment. Local control and overall survival with
conventional radiation therapy have been demonstrated to be sub-
stantially inferior to surgery (5). Local control with conventional
radiation therapy is reported from 40 to 70% with 5-year overall
survival quoted from 7 to 32% (5).
Stereotactic body radiation therapy (SBRT) is becoming the
standard of care in medically inoperable patients with stage I
NSCLC (1). SBRT has been shown to be superior to conven-
tional radiation therapy with local control from 83 to 93% and
3-year overall survival from 47 to 84.7% (4, 6–10). Most of the
data from SBRT have come from clinical trials and single-center
studies at large academic institutions. Data from smaller academic
hospitals are more limited. The goal of this paper is to report the
local recurrence rate and overall survival of patients with stage
I NSCLC treated with SBRT at our institution. Additionally, this
study performs an analysis of the patient, tumor, and treatment
characteristics that predict local control and overall survival.
MATERIALS AND METHODS
PATIENT POPULATION
This is a retrospective review of 78 stage I central and periph-
eral NSCLC tumors in 74 patients treated between December
2006 and July 2012 with SBRT at Winthrop-University Hos-
pital (WUH). Peripheral tumors were defined at those >2 cm
in all directions around the proximal bronchial tree. Patients
www.frontiersin.org October 2014 | Volume 4 | Article 287 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Factor et al. SBRT for stage I NSCLC
who received CyberKnife for stage I NSCLC were identified
from a WUH lung tumor registry. Patients were either medically
inoperable or refused surgery. All patients were seen in conjunc-
tion with the Chairman of Thoracic Surgery to determine eligi-
bility as to operability. It is primarily the decision of the Thoracic
Surgeon who determines if a patient is a candidate for resection
although the pulmonologist is often consulted. All patients had a
PET/CT scan prior to treatment for staging purposes. As a general
rule, PFTs were also obtained primarily to determine resectability.
No patient had a FEV-1 <0.6 l. Patients who received chemother-
apy or mediastinal radiation were excluded. All patients’ radiation
oncology records were subsequently reviewed. This study was
approved by our hospital’s institutional review board.
TREATMENT TECHNIQUE
All 78 tumors were treated using a CyberKnife robotic linear accel-
erator. All patients were immobilized using a thermoplastic cast
with arms up. One fiducial marker was placed at least 5 days
prior either using CT guidance or navigational bronchoscopy to
account for seed migration. CT imaging was performed using
1.5 mm cuts. Planning was performed using Multiplan (Accuray,
Inc., Sunnyvale, CA, USA) inverse planning and delivered using
the CyberKnife (Accuray, Inc.) with motion and respiratory track-
ing performed using the Synchrony system (Accuray, Inc.). For six
tumors, the fiducials were not trackable, and a spine tracking sys-
tem was used for tumor localization. The planning target volume
(PTV) was created by adding a 5-mm margin to the GTV. In gen-
eral, treatment was delivered over four consecutive days for central
tumors to a dose of 4800 cGy delivered in four fractions (11).
Peripheral tumors were treated to a dose of 6000 cGy in three con-
secutive fractions (6). The median dose delivered for all patients
was 4800 cGy in four fractions. The various dose fractionation
schemes are listed in Table 1. Patients treated with alternative dose
fractionation schemes received prior radiation therapy. BED10Gy
was calculated for each of our dose schedules using the formula
nd(1+ d/α/β), where n is the fractionation number, d is the daily
dose, and α/β is assumed to be 10 for tumors. Tissue corrections
and dose heterogeneity corrections were used in the treatment
planning process. Dose constraints for normal tissues were the
same as those used in RTOG 0236 (6).
FOLLOW-UP
The primary endpoints of this study were local control, overall sur-
vival, and toxicities. Recurrence-free survival was also evaluated.
Local failure was defined as tumor recurrence within or immedi-
ately adjacent to the treated field. Local control was defined as the
absence of local failure. Recurrence-free survival was defined as
the time from the end of treatment to occurrence of a local failure,
mediastinal relapse, distant relapse, or death. Patients were fol-
lowed up periodically using either CT scans or combined PET/CT
scans. The most recent CT scan, PET/CT scan, or time to local
failure was noted. Overall survival was determined by the most
recent follow-up or time to death. Follow-up was based primarily
on the radiation oncology records. In addition, any supplemen-
tal notes from other departments sent to the radiation oncology
department were also used. Overall survival was confirmed using
the social security death index.
Table 1 | Dose fractionation schemes.
Dose Number of patients %
30 (15×2) 1 1
32 (8×4) 1 1
40 (10×4) 2 3
40 (8×5) 1 1
45 (15×3) 14 18
48 (12×4) 39 50
60 (15×4) 5 6
60 (20×3) 15 19
STATISTICAL ANALYSIS
Actuarial local control, overall survival, and recurrence-free sur-
vival were calculated using the Kaplan–Meier method. Univariate
analysis was performed using Cox regression. Factors analyzed in
the univariate analysis included BED10Gy, gender, age, and T-stage.
A BED10Gy cut off of 106 Gy was used in the univariate analysis
because this was the median BED10Gy in this study. All statistical
analysis was done in SPSS 21 (IBM, Armonk, NY, USA). Toxicity
was determined using the CTCAE 4.0 classification.
RESULTS
Demographic, tumor, and treatment characteristics are as fol-
lows: the median age was 78.5 years (range 56–93 years). Thirty-six
tumors (46%) were in male patients and 42 tumors (54%) were
in female patients. Thirty-four tumors (44%) were peripherally
located and 44 tumors (56%) were centrally located. Forty-one
tumors (53%) were adenocarcinoma, 23 tumors (29%) squamous
cell carcinoma, 10 tumors (13%) NSCLC, not otherwise specified,
and 4 tumors (5%) had unknown histology. Fifty-two tumors
(67%) were T1 and 26 tumors (33%) were T2.
The median follow-up for local control was 14.4 months. A total
of seven local failures occurred in this study. The median time to
local failure was 17 months with a range from 5 to 53 months. The
2-year local control rate was 87% (Figure 1). Median follow-up
for overall survival was 18.8 months. The 2-year overall survival
was 68% in this patient population (Figure 2). There were 16 cases
(22%) of mediastinal failure, and 10 cases (14%) of distant metas-
tases. There were 25 cases (34%) of recurrence of any form. The
2-year recurrence-free survival was 48.3% (Figure 3).
Table 2 summarizes the univariate analysis of patient, tumor,
and treatment characteristics on 2-year local recurrence and over-
all survival. Only male gender (p= 0.009) was associated with
worse overall survival. Other patient, tumor, or treatment fac-
tors, including age, histology, T-stage, and biologic equivalent dose
(BED10Gy), did not predict overall survival. No factors, including
patient gender, were able to predict local recurrence.
There was one case of grade 2 pneumonitis identified. There
were no reported cases of radiation pneumonitis greater than
grade 2. There were no other toxicities experienced in this study.
DISCUSSION
Clinical trials as well as single-center studies have shown SBRT
to provide far superior local control and overall survival when
compared to conventional radiation therapy in the treatment of
Frontiers in Oncology | Radiation Oncology October 2014 | Volume 4 | Article 287 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Factor et al. SBRT for stage I NSCLC
FIGURE 1 | Kaplan–Meier curve for local control. The median follow-up
for local control was 14.4 months. A total of seven local failures occurred in
this study. The median time to local failure was 17 months with a range
from 5 to 53 months. The 2-year local control rate was 87%.
FIGURE 2 | Kaplan–Meier curve for overall survival. Median follow-up for
overall survival was 18.8 months. The 2-year overall survival was 68% in this
patient population.
clinically inoperable stage I NSCLC, establishing SBRT as the stan-
dard of care in these patients (1, 6–10). The 2-year overall survival
(68%) and 2-year local control (87%) in this study are similar to
clinical trials and studies at larger academic institutions. Table 3
summarizes the results of a number of previous SBRT studies at
large academic institutions and clinical trials.
There are only a limited number of studies using CyberKnife
in the treatment of stage I NSCLC. CyberKnife therapy appears
to have similar success for local control and overall survival to
other tools for delivering SBRT. The local control with CyberKnife
therapy is reported from 85.8 to 100% and the overall survival
is reported from 45 to 87% (12–16). A number of previous
FIGURE 3 | Kaplan–Meier curve for recurrence-free survival. There were
25 cases of recurrence of any form. The 2-year recurrence-free survival was
48.3%.
Table 2 | Univariate analysis of predictors of local control and overall
survival.
Local control Overall survival
2 years
LC (%)
p-Value 2 years
OS (%)
p-Value
Gender Male 78 0.23 57 0.009
Female 92 77
Age <75 92 0.43 64 0.59
≥75 85 70
Histology Adeno 95 0.54 74 0.2
SCC 83 60
TNM T1N0M0 90 0.15 68 0.66
T2N0M0 82 68
BED (Gy10) ≤106 Gy 85 0.36 60 0.85
>106 Gy 92 76
CyberKnife studies are included in Table 4. The study by Vah-
dat et al. included in Table 4 only included patients with stage IA
NSCLC.
Our study found comparable local control and overall survival
to previous CyberKnife studies in the treatment of stage I NSCLC.
Our study has a comparable or superior sample size to many of
the previous CyberKnife studies.
The correlation between overall survival and gender is not
unique to our study. In a single institutional prospective study
of 177 patients with potentially operable stage I NSCLC, Lager-
waard et al. found female gender to have superior overall survival
(p= 0.02) on multivariate analysis (8). Lagerwaard did not find a
correlation between overall survival and any other patient, tumor,
or treatment characteristic.
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Table 3 | Results of previous SBRT studies at large institutions and
clinical trials.
Study Number of
patients
Median
follow-up
(months)
3-year
Local
control
3-year
Overall
survival
Timmerman et al.
(RTOG 0236) (6)
55 34.4 90.6% 55.8%
Baumann et al. (7) 57 34.0 92.0% 60.0%
Crabtree et al. (4) 151 23.4 90.0% 47.0%
Lagerwaard et al. (8) 177 LC-20.0 93.0% 84.7%
OS-31.5
Shibamoto et al. (9) 180 36.0 83.0% 69.0%
Fakiris et al. (10) 70 50.2 88.1% 42.7%
Present study 74 LC-14.4 87.0%
(2-year)
68.0%
(2-year)OS-18.8
Table 4 | Results of previous CyberKnife studies.
Study Number of
patients
Median
follow-up
(months)
2-year
Local
control
2-year
Overall
survival
Chen et al. (12) 40 44.0 91.0%
(3-year)
45.0%
(3-year)
Collins et al. (13) 20 25.0 100% 87.0%
van der Voort
van Zyp et al.
(14)
60 Gy-59 15.0 60 Gy-96.0% 62.0%-all
patients
45 Gy-11 45Gy-78.0%
70 Total
Brown et al. (15) 31 27.5 85.8%
(4.5-year)
83.5%
(4.5-year)
Vahdat et al. (16) 20 43.0 95.0% 90.0%
Present study 74 LC-14.4 87.0% 68.0%
OS-18.8
Similarly, in a multicenter study involving 180 stage I NSCLC
patients, Shibamoto et al. found women to have an overall survival
of 86% and men to have an overall survival of 67% (p= 0.031)
(9). This study also found women as well as younger patients to
have more favorable local recurrence rates. The p-value was 0.027
for women and 0.014 for age ≤76.
The link between female gender and superior overall survival
does not appear to be unique to SBRT. A study by Wilsnivesky
and Halm involving 18,967 elderly patients with stage I and II
NSCLC divided patients into those receiving surgery, those receiv-
ing chemotherapy or radiation but not surgery, and untreated
patients (17). Women were found to have better overall sur-
vival than men in all three groups (p< 0.001). On multivariate
analysis women had better overall survival regardless of treatment
type. Potential explanations for better overall survival of females
included hormonal, genetic, and metabolic factors.
Other studies have demonstrated dose to correlate with local
control and overall survival (18, 19). In a retrospective study
involving 257 patients with stage I NSCLC at 14 institutions,
Onishi et al. found those treated with a BED10Gy of 100 Gy or
more to have statistically significant superior local control and
overall survival to patients receiving a BED10Gy of <100 Gy (18).
Olsen et al. also found improved local control and overall survival
when treated with a BED10Gy of >100 Gy in a single-center study
of 130 patients with early-stage NSCLC (18).
In a study of 505 patients with early-stage NSCLC, Grills et al.
found a BED10Gy of 105 Gy or greater to predict local control (20).
In this study, local recurrence was 15% in patients treated with a
BED10Gy of <105 Gy and 4% in patients receiving a BED10Gy of
105 Gy or greater (p< 0.0001). In our study, a BED10Gy of greater
than or less than 106 likely failed to correlate with local control
because of the smaller sample size of our study.
This study is limited by its relatively small sample size, short
follow-up period, and retrospective design. As in the case of
BED10Gy, it is possible that some of the variables may have achieved
statistical significance with a larger sample size.
In conclusion, our study at a small academic hospital demon-
strates effective local control and overall survival of patients with
stage I NSCLC treated with SBRT. These results are encouraging
for the use of CyberKnife SBRT in the treatment of stage I NSCLC
outside of major academic institutions.
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